Lots of bite-size updates in this episode.

Capitello-281: capivasertib + abiraterone (+ prednisone + ADT)
Adjuvant Belzutifan + Pemroblizumab is FDA approved
Durvalumab approved with BCG for non-muscle invasive bladder cancer
  Insightful commentary: https://doi.org/10.1200/JCO-25-02670
Talquetamab + Durvaluamb - a new safety signal?

Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Breast Cancer Updates and T-Cell Stemness

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.